Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno(National Institutes of Health), James N. Kochenderfer(National Institutes of Health)
Cited by 1,383
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Long-term outcomes following CAR T cell therapy: what we know so far
|Nature Reviews Clinical Oncology|2023|1.2k
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
|Nature Communications|2020|123
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia
|Molecular Therapy — Methods & Clinical Development|2024|5